| Title | Intervention |
NCT ID |
Sponsor | Status |
|---|---|---|---|---|
| Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II... | Exemestane, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery | NCT02598557 | National Cancer Institute (NCI) | Active, not recruiting |
| Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With... | 3-Dimensional Conformal Radiation Therapy, Cognitive Assessment, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment | NCT02635009 | NRG Oncology | Recruiting |
| Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer | Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure | NCT02636582 | National Cancer Institute (NCI) | Active, not recruiting |
| Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors | Carvedilol, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration, Pharmacogenomic Study, Placebo Administration | NCT02717507 | Children's Oncology Group | Active, not recruiting |
| S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) | Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration | NCT02728596 | Southwest Oncology Group | Active, not recruiting |
| Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis | Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Simvastatin, Placebo Administration | NCT02743364 | National Cancer Institute (NCI) | Active, not recruiting |
| DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection | Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rocakinogene Sifuplasmid | NCT02772003 | National Cancer Institute (NCI) | Active, not recruiting |
| The National Myelodysplastic Syndromes (MDS) Study | Therapeutic | NCT02775383 | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting |
| Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive,... | Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim | NCT02780401 | University of Washington | Active, not recruiting |
| Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric... | Curcumin, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Placebo Administration | NCT02782949 | National Cancer Institute (NCI) | Active, not recruiting |
Why I Joined a Clinical Trial
Hi, my name is Raffaellina and [am here] thanks to the European Institute of Oncology and to the research! I am 76 years old and I have been diagnosed [with] breast cancer. I have chosen to participate into a clinical trial because of the clear and accurate explanation of my options and future perspectives and for the confidence in research transmitted by the Team I felt as a” human being” and not as a “number”, and this feeling has not changed afterwards. I was so scared about my future, but when the team proposed me to participate in the study, I have accepted it with enthusiasm. No adverse event occurred, and moreover, I have experienced benefit that impacted the definitive surgery. We need to trust and support clinical research!